Nucleic Acids Research APC and Open Access: Why This Gold OA Journal Costs Less Than You'd Expect

NAR flipped to full gold open access in 2005. At the time, this was radical. Most high-impact journals were still locked behind paywalls, and the concept of APCs was foreign to many researchers.

The decision worked. NAR's citation counts climbed steadily after the transition, and the journal now ranks among the top 20 most-cited journals across all of science. The open access model means every bioinformatician, geneticist, and structural biologist on the planet can read NAR papers without a subscription. That accessibility drives citations, which drives impact factor, which attracts better submissions. It's a virtuous cycle that other journals have tried to replicate with mixed results.

By 2026, NAR's model looks prescient. The journal doesn't need to negotiate hybrid OA options or worry about Plan S compliance. It was already there.

Even though NAR is fully OA and requires an APC for every article, many researchers don't pay out of pocket. Oxford University Press has negotiated Read & Publish (transformative) agreements with institutions and consortia worldwide. Under these deals, the APC is covered as part of the institutional subscription package.

The US situation is, as usual, institution-by-institution. Some universities have full OUP OA agreements. Others have partial coverage or OA funds that can be applied to NAR APCs. Your best move is to check your library's open access page before submission. If your institution has a deal, the APC is covered automatically during the production process.

For institutions without OUP agreements, $3,155 is well within the range of most departmental OA funds. It's less than half what Nature Communications charges.

OUP's waiver system for NAR follows the standard publisher approach:

Automatic waivers: Corresponding authors in Research4Life Group A countries (low-income nations) receive a full APC waiver. No application needed.

50% discount: Authors in Research4Life Group B countries (lower-middle-income) get half off.

Case-by-case waivers: Authors facing genuine financial hardship can request a waiver at the time of acceptance. OUP states that editorial decisions are made independently of ability to pay.

Database and Web Server issues: These special issues have historically offered reduced or waived APCs for accepted papers, though this varies by year. The editorial team can confirm current policy.

Society membership: NAR doesn't have an affiliated society membership that provides discounts, unlike some journals. The APC is the APC.

In practice, the $3,155 price point is low enough that most funded researchers can cover it through standard grant budgets without needing a waiver.

NAR satisfies every major open access mandate without any workarounds:

Because NAR is fully gold OA, there's no embargo period and no need to deposit accepted manuscripts separately. The published version is freely available from day one on the journal website and in PubMed Central. This is the simplest compliance scenario possible.

NAR supports both CC BY and CC BY-NC licenses. If your funder is a cOAlition S member, make sure you select CC BY during the licensing step. CC BY-NC won't satisfy Plan S requirements.

1. The Database Issue is a citation powerhouse. NAR's annual Database Issue, published each January, is one of the most-cited special issues in all of science. Papers describing widely used databases (UniProt, NCBI resources, Ensembl) accumulate thousands of citations. If you maintain a biological database, the Database Issue is the single highest-visibility venue for your update paper.

2. NAR publishes fast. Average time from submission to first decision is around 30 days for regular articles. For the Web Server Issue (published each July), the timeline is structured around a fixed submission deadline, but turnaround remains competitive. Compared to journals like Genome Biology (often 60+ days to first decision), NAR's speed is a real advantage.

3. The journal is enormous. NAR publishes over 2,000 articles per year. This volume means acceptance isn't as competitive as it looks from the IF alone. The acceptance rate hovers around 35-40% for regular research articles, which is significantly higher than Genome Research (~20%) or Nature Genetics (<10%). If your work fits NAR's scope, your odds are reasonable.

NAR covers nucleic acid research broadly, but the journal has clear sweet spots:

• Genomics and gene regulation: Transcriptomics, epigenomics, chromatin biology, CRISPR/gene editing
• Structural biology of nucleic acids: RNA structure, DNA-protein interactions, ribosomes
• Bioinformatics methods: New algorithms, software tools, pipelines (especially if validated on real data)
• Databases and web servers: The annual special issues are the go-to venue
• Synthetic biology: DNA/RNA nanotechnology, aptamers, modified nucleotides

Papers that don't fit: pure protein biochemistry without a nucleic acid angle, clinical studies without a molecular mechanism, and computational methods tested only on simulated data.

NAR is relatively straightforward on fees, but a few things to watch:

• No page charges. The APC covers the full article regardless of length.
• No color figure fees. Color is free in both online and any print versions.
• No submission fee. You only pay at acceptance.
• Supplementary data: Free to include through OUP's hosting. Very large datasets should be deposited in appropriate repositories (GEO, SRA, Dryad). These external repositories are typically free for standard dataset sizes.
• License choice matters. CC BY satisfies all funder mandates. CC BY-NC is available but won't satisfy Plan S. Choose carefully during production.
• Revision timelines: NAR gives authors 3 months for major revisions. If you miss the window, you may need to resubmit as a new manuscript, restarting the process.

NAR is one of the clearest value propositions in molecular biology publishing. You get a top-15 IF, full gold OA, a reasonable APC, and fast turnaround. The journal's scope is broad enough to accommodate everything from wet-lab structural biology to computational genomics.

If your work involves nucleic acids in any substantive way, NAR should be on your shortlist. The APC is manageable, institutional deals often cover it entirely, and the journal's open access model means your paper reaches every researcher who might cite it.

The main reason not to choose NAR is scope mismatch. If your paper is primarily about protein function, cell signaling, or clinical outcomes, you're better served by a journal like PNAS or a discipline-specific title.

For more on how OUP handles open access across its portfolio, visit the Oxford University Press open access page.

Before submitting, make sure your manuscript is ready for NAR's review standards. The journal's acceptance rate is reasonable, but desk rejections still account for a large share of outcomes. Run a free readiness scan to catch formatting issues, missing data availability statements, and other problems that trigger rejection before peer review even begins.